Monogenic vessel diseases related to ischemic stroke: A clinical approach

Journal of Cerebral Blood Flow and Metabolism

Volumn 27, Issue 10, 2007, Pages 1649-1662

  Ballabio, E ^a,b   Bersano, A ^a   Bresolin, N ^a   Candelise, L ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Cerebrovascular abnormalities; Monogenic; Single gene; Stroke

Indexed keywords

ARTERIOSCLEROSIS; ARTERY DISEASE; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL RECESSIVE DISORDER; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; EHLERS DANLOS SYNDROME; ENDOTHELIAL DYSFUNCTION; FABRY DISEASE; GENETIC DISORDER; HUMAN; INHERITANCE; KIDNEY DISEASE; LEUKOENCEPHALOPATHY; MARFAN SYNDROME; MONOGENIC DISORDER; MOYAMOYA DISEASE; NEUROFIBROMATOSIS; PHENOTYPE; PRIORITY JOURNAL; PSEUDOXANTHOMA ELASTICUM; RETINOPATHY; REVIEW; STROKE;

CEREBROVASCULAR ACCIDENT; HUMANS; VASCULAR DISEASES;

EID: 34748820096     PISSN: 0271678X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jcbfm.9600520     Document Type: Review

References (122)

1. Arima K, Yanagawa S, Ito N, Ikeda S (2003) Cerebral arterial pathology of CADASIL and CARASIL. (Maeda syndrome). Neuropathology 23:327-34
2. Artavanis-Tsakonas S, Matsuno K, Fortini ME (1995) Notch signaling. Science 268:225-32
3. Battistella PA, Carollo C (1997) Clinical and neuroradiological findings of Moyamoya disease in Italy. Clin Neurol Neurosurg 99:S54-7
4. Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup RJ (1998) Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997 Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK). Am J Med Genet 77:31-7
5. Bergen AA, Plomp AS, Schuurman EJ, Terry S, Breuning M, Dauwerse H et al. (2000) Mutations in ABCC6 cause pseudoxanthoma elasticum. Nat Genet 25:228-31
6. Boileau C, Jondeau G, Mizuguchi T, Matsumoto N (2005) Molecular genetics of Marfan syndrome. Curr Opin Cardiol 20:194-200
7. Borota L, Bajic R, Marinkovic S, Makismovic R, Markovic Z, Kovacevic M (1997) The main epidemiological, clinical and morphological features of Moyamoya disease in Yogoslavia. Clin Neurol Neurosurg 99:S49-53
8. Boutouyrie P, Germain DP, Fiessinger JN, Laloux B, Perdu J, Laurent S (2004) Increased carotid wall stress in vascular Ehlers-Danlos syndrome. Circulation 109:1530-5
9. Brady RO (1967) Enzymatic abnormalities in diseases of sphingolipid metabolism. Clin Chem 13:565-77
10. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L (1967) Enzymatic defect in Fabry's disease ceramidetrihexosidase deficiency. New Engl J Med 276:1163-7
11. Brulin P, Godfraind C, Leteurtre E, Ruchoux MM (2002) Morphometric analysis of ultrastructural vascular change in CADASIL: analysis of 50 skin biopsy specimens and pathogenic implications. Acta Neuropathol 104:241-8
12. Bruno A, Adams HP, Biller J, Rezai K, Cornell S, Aschenbrener CA (1988) Cerebral infarction due to moyamoya disease in young adults. Stroke 19:826-33
13. Chabriat H, Joutel A, Vahedi K, Iba-Zizen MT, Tournier-Laserve E, Bousser MG (2000) CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy): clinical features and neuroimaging. Bull Acad Natl Med 184:1523-31
14. Chabriat H, Levy C, Taillia H, Iba-Zizen MT, Vahedi K, Joutel A et al. (1998) Patterns of MRI lesions in CADASIL. Neurology 51:452-7
15. Chabriat H, Vahedi K, Iba-Zizen MT, Joutel A, Nibbio A, Nagy TG et al. (1995) Clinical spectrum of CADASIL: a study of 7 families. The Lancet 346:934-9
16. Chassaing N, Martin L, Calvas P, Le Bert M, Hovnanian A (2005) Pseudoxanthoma elasticum: a clinical, pathophysiological and genetic update including 11 novel ABCC6 mutations. J Med Genet 42:881-92
17. Christen-Zach S, Huber M, Struk B, Lindpaintner K, Munier F, Panizzon RG et al. (2006) Pseudoxanthoma elasticum: evaluation of diagnostic criteria based on molecular data. Br J Dermatol 155:89-93
18. Cohn AC, Kotschet K, Veitch A, Delatycki MB, McCombe MF (2005) Novel ophthalmological features in hereditary endotheliopathy with retinopathy, nephropathy and stroke syndrome. Clin Experiment Ophthalmol 33:181-3
19. Conway JE, Hutchins GM, Tamargo RJ (1999) Marfan syndrome is not associated with intracranial aneurysms. Stroke 308:1632-6
20. Creange A, Zeller J, Rostaing-Rigattieri S, Brugieres P, Degos JD et al. (1999) Neurological complications of neurofibromatosis type 1 in adulthood. Brain 122:473-81
21. Crutchfield KE, Patronas NJ, Dambrosia JM, Frei KP, Banerjee TK, Barton NW et al. (1998) Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 50:1746-9
22. Daston MM, Scrable H, Nordlund M, Sturbaum AK, Nissen LM, Ratner N (1992) The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes. Neuron 8:415-28
23. Davous P (1998) CADASIL: a review with proposed diagnostic criteria. Eur J Neurol 5:219-33
24. De Paepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE (1996) Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 62:417-26
25. De Paepe A, Malfait F (2004) Bleeding and bruising in patients with Ehlers-Danlos syndrome and other collagen vascular disorders. Br J Haematol 127:491-500
26. Deegan P, Baehner AF, Barba-Romero MA, Hughes D, Kampmann C, Beck M (2006) Natural history of Fabry disease in females in the Fabry outcome survey. J Med Genet 43:347-52
27. Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M et al. (2003) Fabry disease, an underrecognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138:338-46
28. Desnick RJ, Joannou YA, Eng CM (2001) α-Galactosidase A deficiency: Fabry disease. In: The metabolic and molecular bases of inherited disease (Scriver CR, Beaudet AL, Sly WS, Valle D, eds), 8th edn, New York: McGraw-Hill, 37-74
29. Dichgans M, Holtmannspotter M, Herzog J, Peter N, Bergmann M, Yousry TA (2002) Cerebral microbleeds in CADASIL a gradient-echo magnetic resonance imaging and autopsy study. Stroke 33:67-71
30. Dichgans M, Ludwig H, Muller-Hocker J, Messerschmidt A, Gasser T (2000) Small in-frame deletions and missense mutations in CADASIL: 3D models predict misfolding of Notch3 EGF-like repeat domains. Eur J Hum Genetics 8:280-5
31. Dichgans M, Mayer M, Uttner I, Bruning R, Muller-Hocker J, Rungger G et al. (1998) The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol 44:731-9
32. Dotti MT, Federico A, Mazzei R, Bianchi S, Scali O, Conforti FL et al. (2005) The spectrum of Notch3 mutations in 28 Italian CADASIL families. J Neurol Neurosurg Psychiatry 7:736-8
33. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S et al. (2001) International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human (alpha)-Galactosidase A replacement therapy in Fabry's disease. New Engl J Med 345:9-16
34. Friedman JM (1999) Epidemiology of neurofibromatosis type 1. Am J Med Genet 89:1-6
35. Friedman JM, Arbiser J, Epstein JA, Gutmann DH, Huot SJ, Lin AE et al. (2002) Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med 4:105-11
36. Fukui M, Members of the Research Committee on spontaneous Occlusion of the Circle of Willis (Moyamoya disease) of Ministry and Welfare, Japan (1997) Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis (Moyamoya' disease) of the Ministry of Healthand Welfare, Japan. Clin Neurol Neurosurg 99:S238-40
37. Fukutake T (1999) Young-adult-onset hereditary subcortical vascular dementia: cerebral autosomal recessive arteriosclerosis with subcortical infarcts and leukoencephalopathy (CARASIL). Rinsho Shinkeigaku 39:50-2
38. Fukutake T, Hirayama K (1995) Familial young-adult-onset arteriosclerotic leukoencephalopathy with alopecia and lumbago without arterial hypertension. Eur Neurol 35:69-79
39. Garzuly F, Marodi L, Erdos M, Grubits J, Varga Z, Gelpi E et al. (2005) Megadolichobasilar anomaly with thrombosis in a family with Fabry's disease and a novel mutation in the alpha-galactosidase A gene. Brain 128:2078-83
40. Germain DP (2002) Clinical and genetic features of vascular Ehlers-Danlos syndrome. Ann Vasc Surg 16:391-7
41. Gheduzzi D, Guidetti R, Anzivino C, Tarugi P, Di Leo E, Quaglino D et al. (2004) ABCC6 mutations in Italian families affected by pseudoxanthoma elasticum (PXE). Hum Mutat 24:438-9
42. Grunfeld JP, Lidove O, Joly D, Barbey F (2001) Renal disease in Fabry patients. J Inherit Metab Dis 24:S71-S74
43. Hamilton SJ, Friedman JM (2000) Insights into the pathogenesis of neurofibromatosis 1 vasculopathy. Clin Genet 58:341-4
44. Han DH, Kwon OK, Byun BJ, Choi BY, Choi CW, Choi JU et al. (2000) A Co-Operative Study: clinical characteristics of 334 korean patients with Moyamoya disease treated at neurosurgical institutes (1976 to 1994). Acta Neurochirurgica 142:1263-74
45. Hassan A, Markus HS (2000) Genetics and ischaemic stroke. Brain 123:1784-812
46. Hassan A, Sham PC, Markus HS (2002) Planning genetic studies in human stroke: sample size estimates based on family history data. Neurology 58:1483-8
47. Heaton JP, Wilson JW (1986) Pseudoxanthoma elasticum and its urological implications. J Urol 135:776-7
48. Houkin K, Abe H, Yoshimoto T, Takahashi A (1996) Is unilateral Moyamoya disease different from Moyamoya disease? J Neurosurg 85:772-6
49. Hu X, Plomp AS, van Soest S, Wijnholds J, de Jong PT, Bergen AA (2003) Pseudoxanthoma elasticum: a clinical, histopathological, and molecular update. Surv Ophthalmol 48:424-38
50. Ikeda E (1991) Sistemic vascular changes in spontaneous occlusion of the circle of Willis. Stroke 22:1358-62
51. Ikeda H, Sasaki T, Yoshimoto T, Fukui M, Arinami T (1999) Mapping of familial Moyamoya disease gene to chromosome 3p24.2-p26. Am J Hum Genet 64:533-7
52. Ikezaki K, Han DH, Kawano T, Kinukawa N, Fukui M (1997a) A clinical comparison of definite Moyamoya disease between South Korea and Japan. Stroke 28:2513-7
53. Ikezaki K, Inamura T, Kawano T, Fukui M (1997b) Clinical features of probable Moyamoya disease in Japan. Clin Neurol Neurosurg 99:S173-7
54. Jen J, Cohen AH, Yue Q, Stout JT, Vinters HV, Nelson S et al. (1997) Hereditary endotheliopathy with retinopathy, nephropathy, and stroke (HERNS). Neurology 49: 1322-1330
55. Joutel A, Chabriat H, Vahedi K, Domenga V, Vayssiere C, Ruchoux MM et al. (2000) Splice site mutation causing a seven amino acid Notch3 in-frame deletion in CADASIL. Neurology 54:1874-5
56. Joutel A, Ducros A, Alamowitch S, Cruaud C, Domenga V, Marechal E et al. (1996) A human homolog of bacterial acetolactate synthase genes maps within the CADASIL critical region. Genomics 38:192-8
57. Joutel A, Favrole P, Labauge P, Chabriat H, Lescoat C, Andreux F et al. (2001) Skin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosis. The Lancet 358:2049-51
58. Joutel A, Vahedi K, Corpechot C, Troesch A, Chabriat H, Vayssiere C et al. (1997) Strong clustering and stereo-typed nature of Notch3 mutations in CADASIL patients. The Lancet 350:1511-5
59. Judge DP, Dietz HC (2005) Marfan's syndrome. Lancet 366:1965-76
60. Kolodny EH, Pastores GM (2002) Anderson-Fabry disease: extrarenal, neurologic manifestations. J Am Soc Nephrol 13:S3-150
61. Kuroda S, Ishikawa T, Houkin K, Iwasaki Y (2002) Clinical significance of posterior cerebral artery stenosis/occlusion in Moyamoya disease. No Shinkei Geka 30:1295-300
62. Laube S, Moss C (2005) Pseudoxanthoma elasticum. Arch Dis Child 90:754-6
63. Le Charpentier Y, Crouzet J, Le Charpentier M, Lessana-Leibowitch M, Di Crescenzo MC, Bennett B et al. (1981) Fabry's disease without cutaneous angiokeratoma : diagnosis by electron microscope study of skin biopsy (author's translation). Sem Hop 57:78-82. French
64. Lebwohl M, Phelps RG, Yannuzzi L, Chang S, Schwartz I, Fuchs W (1987) Diagnosis of pseudoxanthoma elasticum by scar biopsy in patients without characteristic skin lesions. New Engl J Med 317:347-50
65. Lesnik Oberstein S, van den Boom R, van Buchem MA, van Houwelingen HC, Bakker E, Vollebregt E, Ferrari M et al. (2001) Cerebral microbleeds in CADASIL. Neurology 57:1066-70
66. Linhart A, Lubanda JC, Palecek T, Bultas J, Karetova D, Ledvinova J et al. (2001) Cardiac manifestations in Fabry disease. Inherit Metab Dis 124:75-83
67. Linthorst GE, De Rie MA, Tjiam KH, Aerts JM, Dingemans KP, Hollak CE (2004) Misdiagnosis of Fabry disease: importance of biochemical confirmation of clinical or pathological suspicion. Br J Dermatol 150:575-7
68. Loeys B, De Backer J, Van Acker P, Wettinck K, Pals G, Nuytinck L et al. (2004) Chomprehensive molecular screening of the FBN1 gene favors locus homogeneity of classical Marfan syndrome. Hum Mutat 24:140-6
69. Loeys B, Nuytinck l, Delvaux I, De Bie S, De Peape A (2001) Genotype and phenotype analysis of 171 patients referred for molecular study of the fibrillin-1 gene FBN1 because suspected Marfan syndrome. Arch Intern Med 161:2447-54
70. MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38:769-75
71. Markus HS, Martin RJ, Simpson MA, Dong YB, Ali N, Crosby AH et al. (2002) Diagnostic strategies in CADASIL. Neurology 59:1134-8
72. Mehta A, Ginsberg L, FOS Investigators (2005) Natural history of the cerebrovascular complications of Fabry disease. Acta Paediatr 94:24-7
73. Mehta A, Ricci R, Widemer U, Dehout F, Garcia de Lorenzo A, Kampmann C et al. (2004) Fabry disease defined: vaseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34:236-42
74. Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281:249-54
75. Mitsias P, Levine SR (1996) Cerebrovascular complications of Fabry's disease. Ann Neurol 40:8-17
76. Mizuguchi T, Collod-Beroud G, Akiyama T, Abifadel M, Harada N, Morisaki T et al. (2004) Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet 36:855-60
77. Moore DF, Ye F, Schiffmann R, Butman JA (2003) Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. AJNR Am J Neuroradiol 24:1096-101
78. Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A et al. (2003) Fabry disease: detection of undiagnosed hemodialysis patients and identification of a 'renal variant' phenotype. Kidney Int 64:801-7
79. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M et al. (1995) An atypical variant of Fabry's disease in men with left ventricular hypertrophy. New Engl J Med 333:288-93
80. Norton KK, Xu J, Gutmann DH (1995) Expression of the neurofibromatosis I gene product, neurofibromin, in blood vessel endothelial cells and smooth muscle. Neurobiol Dis 2:13-21
81. Numaguchi Y, Gonzalez CF, Davis PC, Monajati A, Afshani E, Chang J et al. (1997) Moyamoya disease in the United States. Clin Neurol Neurosurg S26-30
82. O'Sullivan M, Jarosz JM, Martin RJ, Deasy N, Powell JF, Markus HS (2001) MRI hyperintensities of the temporal lobe and external capsule in patients with CADASIL. Neurology 56:628-34
83. Oderich GS, Panneton JM, Bower TC, Lindor NM, Cherry KJ, Noel AA et al. (2005) The spectrum, management and clinical outcome of Ehlers-Danlos syndrome type IV: a 30-year experience. J Vasc Surg 42:98-106
84. Opherk C, Peters N, Herzog J, Luedtke R, Dichgans M (2004) Long-term prognosis and causes of death in CADASIL: a retrospective study in 411 patients. Brain 127:2533-9
85. Ophoff RA, DeYoung J, Service SK, Joosse M, Caffo NA, Sandkuijl LA et al. (2001) Hereditary vascular retinopathy, cerebroretinal vasculopathy, and hereditary endotheliopathy with retinopathy, nephropathy, and stroke map to a single locus on chromosome 3p21.1-p21.3. Am J Hum Genet 69:447-53
86. Osawa M, Kanai N, Kawai M, Fukuyama Y (1995) Clinical genetic study on the idiopatic occlusion of the circle of Willis. In: The research committee on spontaneous occlusion of the circle of Willis (Moyamoya disease) of the Ministry of Health and Welfare in Japan. Annual Report Tokyo, Japan: Ministry of Health and Welfare, Japan 1992 147-52
87. Pastores GM, Lien YH (2002) Biochemical and molecular genetic basis of Fabry disease. J Am Soc Nephrol 13:130-3
88. Pavlovic AM, Zidverc-Trajkovic J, Milovic MM, Pavlovic DM, Jovanovic Z, Mijajlovic M et al. (2005) Cerebral small vessel disease in pseudoxanthoma elasticum: three cases. Can J Neurol Sci 32:115-8
89. Pepin M, Schwarze U, Superti-Furga A, Byers PH (2000) Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. New Engl J Med 342:673-80
90. Plomp AS, Hu X, de Jong PT, Bergen AA (2004) Does autosomal dominant pseudoxanthoma elasticum exist? Am J Med Genet A 126:403-12
91. Pyeritz RE (2000) The Marfan syndrome. Annu Rev Med 51:481-510
92. Razvi SS, Davidson R, Bone I, Muir KW (2005) The prevalence of cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) in the west of Scotland. J Neurol Neurosurg Psychiatry 76:739-41
93. Ringpfeil F, Lebwohl MG, Christiano AM, Uitto J (2000) Pseudoxanthoma elasticum: mutations in the MRP6 gene encoding a transmembrane ATP-binding cassette (ABC) transporter. Proc Natl Acad Sci USA 97:6001-6
94. Robinson PN, Booms P, Katzke S, Ladewig M, Neumann L, Palz M et al. (2002) Mutations of FBN1 and genotype-phenotype correlations in Marfan syndrome and related fibrillinopathies. Hum Mutat 20:153-61
95. Rolfs A, Bottcher T, Zschiesche M, Morris P, Winchester B, Bauer P et al. (2005) Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 366:1794-6
96. Rosser TL, Vezina G, Packer RJ (2005) Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1. Neurology 64:553-5
97. Rubattu S, Giliberti R, Volpe M (2000) Etiology and pathophysiology of stroke as a complex trait. Am J Hyperten 13:1139-48
98. Rubio A, Rifkin D, Powers JM, Patel U, Stewart J, Faust P et al. (1997) Phenotypicn variability of CADASIL and novel morphologic findings. Acta Neuropathol 94: 247-254
99. Ruchoux MM, Maurage CA (1997) CADASIL: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. J Neuropathol Exp Neurol 56:947-64
100. Schafer E, Baron K, Widmer U, Deegan P, Neumann HP, Sunder-Plassmann G et al. (2005) Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease. Hum Mutat 25:412
101. Schievink WI, Michels VV, Piepgras DG (1994) Neurovascular manifestations of heritable connective tissue disorders. Stroke 25:889-903
102. Schiffmann R, Kopp JB, Austin HA, Sabnis S, Moore DF, Weibel T et al. (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743-9
103. Shen MH, Harper PS, Upadhyaya M (1996) Molecular genetics of neurofibromatosis type 1 (NF1). J Med Genet 33:2-17
104. Sherer DW, Bercovitch L, Lebwohl M (2001) Pseudoxanthoma elasticum: significance of limited phenotypic expression in parents of affected offspring. J Am Acad Dermatol 44:534-7
105. Sorensen Sa (2002) Genetic aspects of Fabry disease. In: European Symposium on Fabry Disease, Athens 8-9 November. Abstracts of plenary lectures; 2
106. Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H et al. (2006) High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 79:31-40
107. Struk B, Neldner KH, Rao VS, St Jean P, Lindpaintner K (1997) Mapping of both autosomal recessive and dominant variants of pseudoxanthoma elasticum to chromosome 16p13.1. Hum Mol Genet 6:1823-8
108. Superti-Furga A, Gugler E, Gitzelmann R, Steinmann B (1988) Ehlers-Danlos syndrome type IV: a multi-exon deletion in one of the two COL3A1 alleles affecting structure, stability, and processing of type III procollagen. J Biol Chem 263:6226-32
109. Suzuki J, Takaku A (1969) Cerebrovascular 'moyamoya' disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 20:288-99
110. Tonsgard JH (2006) Clinical manifestations and management of neurofibromatosis type 1. Semin Pediatr Neurol 13:2-7
111. Tournier-Lasserve E, Joutel A, Melki J, Weissenbach J, Lathrop GM, Chabriat H et al. (1993) Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19q12. Nat Genetics 3:256-9
112. Trip MD, Smulders YM, Wegman JJ, Hu X, Boer JM, ten Brink JB et al. (2002) Frequent mutation in the ABCC6 gene (R1141X) is associated with a strong increase in the prevalence of coronary artery disease. Circulation 106:773-5
113. van den Berg JS, Hennekam RC, Cruysberg JR, Steijlen PM, Swart J, Tijmes N et al. (2000) Prevalence of symptomatic intracranial aneurysm and ischaemic stroke in pseudoxanthoma elasticum. Cerebrovasc Dis 10:315-9
114. van den Berg JS, Limburg M, Hennekam RC (1996) Is Marfan syndrome associated with symptomatic intracranial aneurysms? Stroke 271:10-2
115. van den Boom R, Lesnik Oberstein SA, Ferrari MD, Haan J, van Buchem MA (2003) Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: MR imaging findings at different ages 3rd-6th decades. Radiology 229:683-90
116. von Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, Hubner G, Olsen EG et al. (1991) An atypical variant of Fabry's disease with manifestations confined to the myocardium. New Engl J Med 324:395-9
117. Ward BA, Gutmann DH (2005) Neurofibromatosis 1: from lab bench to clinic. Pediatr Neurol 32:221-8
118. Weiss B, Bollag G, Shannon K (1999) Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Am J Med Genet 89:14-22
119. Wityk R, Zanferrari C, Oppenheimer S (2002) Neurovascular complications of Marfan syndrome: a retrospective, hospital-based study. Stroke 33:680-4
120. Yamauchi T, Tada M, Houkin K, Tanaka T, Nakamura Y, Kuroda S et al. (2000) Linkage of familial Moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25. Stroke 31:930-935
121. Yanagawa S, Ito N, Arima K, Ikeda S (2002) Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy. Neurology 58:817-20
122. Yonekawa Y, Ogata N, Kaku Y, Taub E, Imhof HG (1997) Moyamoya disease in Europe, past and present status. Clin Neurol Neurosurg 99 2:S58-60